Bionomics
Bionomics Limited is a clinical-stage biopharmaceutical company based in Thebarton, Australia, specializing in the discovery and development of novel therapeutics for central nervous system disorders and cancer. The company’s leading drug candidate, BNC210, is a negative allosteric modulator aimed at treating anxiety, panic, agitation, and post-traumatic stress disorder, having completed phase 2 clinical trials. Additionally, Bionomics is developing BNC375, a small molecule therapeutic for cognitive impairment associated with Alzheimer's disease, and BNC101, a monoclonal antibody targeting cancer stem cells that has completed phase 1 trials. BNC105, another key compound, is a vascular disrupting agent currently in phase 2 trials for refractory colorectal cancer and phase 1 trials for relapsed/refractory chronic lymphocytic leukemia. The company also offers ionX, an integrated platform of genomics discoveries and technologies. Bionomics has established strategic partnerships with several organizations, including Merck & Co., and was founded in 1996.
Prestwick Chemical offers smart chemical screening libraries, medicinal chemistry services to accelerate development of innovative small molecule drugs. Prestwick Chemical is a French Contract Research Organization (CRO) founded in 1999 by Professor C.G. Wermuth, globally recognized for his expertise in pharmacology and medicinal chemistry. Focused on early drug discovery, the company works for pharmaceutical and biotechnology companies, research institutes as well as academic groups. Projects in cosmetics, veterinary and agro pharmaceutical are also successfully carried on. During the past decade, Prestwick Chemical has gained international recognition for its input to boost drug discovery process through: Tailor-made medicinal chemistry services Smart chemical screening libraries
Eclipse Therapeutics, Inc. ("Eclipse") is a private biotechnology company dedicated to the discovery and development of therapeutics that target cancer stem cells (CSCs) and other forms of innovative cancer treatment.
Iliad Chemicals Pty Limited develops a library of novel molecules that act as potent tubulin polymerisation inhibitors for treating cancer. The company utilizes MultiCore Chemistry technology platform to provide synthesis of molecules and develop chemical libraries.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.